tert-Butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate

Catalog No. :
ACWUMM927
CAS No. :
1001180-18-2
Molecular Formula :
C17H26N4O3
Molecular Weight :
334.42

IUPAC Name:tert-butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate

tert-Butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-((5R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazine-1-carboxylate
MDL No.MFCD29048725
Molecular FormulaC17H26N4O3
Molecular Weight334.42
SMILESO=C(N1CCN(C2=C([C@H](C)CC3O)C3=NC=N2)CC1)OC(C)(C)C
InChI KeyFJZNFQTYLHVIML-JHJMLUEUSA-N
Synonym1-Piperazinecarboxylic acid, 4-[(5R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-, 1,1-dimethylethyl ester
CAS No.1001180-18-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACWUMM927 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACWUMM927 route product structure diagram
    ACWUMM9271001180-18-2
Inquiry

2. ACWUMM927 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVBYD490 route compound structure diagram
    ACVBYD4901001180-21-7 In Stock
  2. Then
  3. ACWUMM927 route product structure diagram
    ACWUMM9271001180-18-2
Inquiry

Comments (0)